[go: up one dir, main page]

AR109858A1 - METHODS THAT USE HDAC11 INHIBITORS - Google Patents

METHODS THAT USE HDAC11 INHIBITORS

Info

Publication number
AR109858A1
AR109858A1 ARP170102934A ARP170102934A AR109858A1 AR 109858 A1 AR109858 A1 AR 109858A1 AR P170102934 A ARP170102934 A AR P170102934A AR P170102934 A ARP170102934 A AR P170102934A AR 109858 A1 AR109858 A1 AR 109858A1
Authority
AR
Argentina
Prior art keywords
hdac11
inhibitors
methods
patient
diseases
Prior art date
Application number
ARP170102934A
Other languages
Spanish (es)
Original Assignee
Forma Therapeutics Inc
H Lee Moffitt Cancer Ct & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc, H Lee Moffitt Cancer Ct & Res filed Critical Forma Therapeutics Inc
Publication of AR109858A1 publication Critical patent/AR109858A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente provee métodos y usos de inhibidores de histona desacetilasa 11 (HDAC11) en el tratamiento de enfermedades y/o trastornos, como, por ejemplo, enfermedades proliferativas celulares. Reivindicación 1: Un método para inhibir o reducir la proliferación de células cancerosas en un paciente que lo necesita, que comprende administrarle un inhibidor de HDAC11 al paciente.This provides methods and uses of histone deacetylase 11 (HDAC11) inhibitors in the treatment of diseases and / or disorders, such as, for example, cell proliferative diseases. Claim 1: A method of inhibiting or reducing the proliferation of cancer cells in a patient in need, comprising administering an HDAC11 inhibitor to the patient.

ARP170102934A 2016-10-20 2017-10-20 METHODS THAT USE HDAC11 INHIBITORS AR109858A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662410766P 2016-10-20 2016-10-20

Publications (1)

Publication Number Publication Date
AR109858A1 true AR109858A1 (en) 2019-01-30

Family

ID=65351696

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102934A AR109858A1 (en) 2016-10-20 2017-10-20 METHODS THAT USE HDAC11 INHIBITORS

Country Status (1)

Country Link
AR (1) AR109858A1 (en)

Similar Documents

Publication Publication Date Title
MX383484B (en) METHOD FOR TREATING CANCER.
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
MX2016007351A (en) COMBINATION THERAPY TO TREAT CANCER.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2018002344A (en) Method for treating cancer.
MX382902B (en) NOTH PATHWAY INHIBITOR IN COMBINATION WITH AN IMMUNOTHERAPEUTIC AGENT FOR USE IN THE TREATMENT OF CANCER.
DOP2017000268A (en) METHODS AND KITS TO TREAT DEPRESSION
CR20150217A (en) HISTONE DEMETILASE INHIBITORS
WO2016025635A3 (en) Combination therapy for treating cancer
NI201600051A (en) COMBINATIONS OF HISTONE DESACETILASE INHIBITORS AND IMMUNOMODULATING DRUGS
MX391720B (en) COMBINATION THERAPY TO TREAT CANCER.
MX383866B (en) EZH2 INHIBITORS FOR TREATMENT OF LYMPHOMAS.
CR20190394A (en) AUTOTAXIN INHIBITOR COMPOUNDS(Divisional de Exp. 2016-0289)
MX2019010601A (en) Combination therapy for treating cancer.
MX374452B (en) GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES.
MX2015010791A (en) Methods of treating cancer and preventing drug resistance.
WO2016043874A3 (en) Combination therapy for treating cancer
ECSP16008797A (en) DERIVATIVES OF HETEROBICICLOARIL AS RORC2 INHIBITORS AND METHODS OF USE OF THE SAME
MX374749B (en) COMBINATION THERAPY INCLUDING A TOR KINASE INHIBITOR AND A CYTIDINE ANALOGUE TO TREAT CANCER.
BR112017026535A2 (en) compound of formula I, isolated enantiomer, pharmaceutical composition, method for inhibiting mct4 monocarboxylate transporter activity, method for selectively inhibiting mct4 monocarboxylate transporter activity, method for treating a mct4 monocarboxylate transporter mediated disorder and use of a compound
BR112017018198A2 (en) inhibition of olig2 activity
MX2019013862A (en) Combination therapy.
BR112018068027A2 (en) method for treating cancer in a patient and pharmaceutical composition
MX394015B (en) INHIBITION OF OLIG2 ACTIVITY.
BR112016016901A2 (en) agents for use in the treatment of retinal inflammation

Legal Events

Date Code Title Description
FB Suspension of granting procedure